Erytech Pharma S.A. (ERYP)
Stock Price:
$6.03 USD
-0.41 (-6.37%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
114.53M |
| Revenue (ttm) |
5.94M |
| Net Income (ttm) |
-62.66M |
| Shares Out |
18.99M |
| EPS (ttm) |
-2.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$6.03 |
| Previous Close |
$6.44 |
| Change ($) |
-0.41 |
| Change (%) |
-6.37% |
| Day's Open |
6.38 |
| Day's Range |
6.03 - 6.38 |
| Day's Volume |
2,114 |
| 52-Week Range |
5.52 - 13.95 |
More Stats
| Market Cap |
114.53M |
| Enterprise Value |
48.13M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.99M |
| Float |
18.34M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-2.79 |
| FCF / Share |
-3.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1,805 |
| Short Ratio |
0.55 |
| Short % of Float |
0.01% |
| Beta |
1.46 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
19.29 |
| PB Ratio |
1.98 |
| Revenue |
5.94M |
| Operating Income |
-71.99M |
| Net Income |
-62.66M |
| Free Cash Flow |
-71.27M |
| Net Cash |
66.39M |
| Net Cash / Share |
3.49 |
| Gross Margin |
100.00% |
| Operating Margin |
-1,212.83% |
| Profit Margin |
-1,186.00% |
| FCF Margin |
-1,200.59% |
| ROA |
-36.86% |
| ROE |
-81.29% |
| ROIC |
-234.00% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$22.12*
(266.83% upside)
Low
13.0
Current: $6.03
High
30.0
Target: 22.12
*Average 12-month USD price target from 4 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 5.28 | 4.45 | 3.36 | 4.14 | 2.93 |
| Revenue Growth | 18.8% | 32.19% | -18.7% | 41.28% | - |
| Gross Profit | 5.28 | 4.45 | 3.36 | 4.14 | 2.93 |
| Operating Income | -64.07 | -43.62 | -30.89 | -22.39 | -15.58 |
| Net Income | -62.66 | -38.22 | -33.53 | -21.91 | -15.01 |
| Shares Outstanding | 17.94 | 17.94 | 17.06 | 17.06 | - |
| Earnings Per Share | -3.49 | -2.13 | -2.95 | -2.74 | -2.16 |
| Operating Cash Flow | -43.31 | -47.86 | -24.70 | -17.61 | -14.58 |
| Capital Expenditures | -20.12 | -5.64 | -1.66 | -1.75 | -0.27 |
| Free Cash Flow | -63.43 | -53.49 | -26.37 | -19.37 | -14.85 |
| Cash & Equivalents | 73.21 | 134 | 186 | 37.65 | 45.63 |
| Total Debt | 14.12 | 2.02 | 2.84 | 2.87 | 0.71 |
| Net Cash / Debt | 59.09 | 132 | 183 | 34.78 | 44.93 |
| Assets | 119 | 168 | 195 | 44.97 | 53.00 |
| Liabilities | 32.99 | 22.24 | 13.84 | 9.33 | 5.87 |
| Book Value | 85.56 | 146 | 181 | 35.64 | 47.13 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Erytech Pharma S.A. |
| Country |
France |
| Employees |
206 |
| CEO |
Gil Beyen |
Stock Information
| Ticker Symbol |
ERYP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ERYP |
Description
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.